ω-conotoxin MVIIA, also knwn as Ziconotide acetate, is a peptide consisting of 25 amino acid. It is a disulfide-bridged polypeptide from the venom of the sea snail Conusmagus that binds to neuronal N-type calcium channels. It forms a compact folded structure, presenting a loop between Cys8 and Cys15 that contains a set of residues critical for its binding. Both ω-conotoxins GVIA and MVIIA could bind to neuronal N-type calcium channels. ω-conotoxin GVIA is rich in hydroxyl groups while ω-conotoxin MVIIA contains a large number of positively charged side chains[1-2].
Ziconotide acetate (ω-Conotoxin MVIIA), the peptide toxin of the Conus magus (cone snail) is a selective antagonist of N-type voltage sensitive calcium channels (VSCC). As a most well-known identified conotoxin so far, it has been used as a effective drug to treat intractable chronic pain in cancer and ADIS patients[2]. Blocks neurotransmitter release by preventing depolarization-induced calcium influx. Used as a ligand for binding studies of voltage sensitive calcium channels. Analgesic; neuroprotective.
ω-Conotoxin MVIIA functions as a selective inhibitor of N-type voltage-sensitive calcium channels (VSCCs). It has analgesic and neuroprotective effects. ω-Conotoxin MVIIA is used to treat neuropathic pain.
Neuronal N-type Ca2+ channel blocker in mammalian and amphibian brain; blocks release of GABA and glutamate at neuronal synapses.
[1] Wang R, et al. Development of an ic-ELISA and immunochromatographic strip based on IgG antibody for detection of ω-conotoxin MVIIA. Journal of Hazardous Materials, 2019; 378: 120510.
[2] Zhou Y, et al. A Chemoenzymatic Approach To Produce a Cyclic Analogue of the Analgesic Drug MVIIA (Ziconotide). Angew. Chem. Int. Ed., 2023; 62: e202302812.
